Background The RTS, S/AS01 vaccine targets the circumsporozoite protein of Plasmodium
falciparum and has partial protective efficacy against clinical and severe malaria disease in …

Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …

Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …

Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

After more than four decades of basic research and clinical trials, the World Health
Organization (WHO) has recommended the malaria vaccine RTS, S for widespread use …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The RTS, S/AS malaria vaccine is being developed for delivery through the
World Health Organization's Expanded Program on Immunization (EPI). We assessed the …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …